BMY - Bristol-Myers Squibb Company

NYSE - NYSE Delayed Price. Currency in USD
50.98
+0.85 (+1.70%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close50.13
Open50.44
Bid50.11 x 1000
Ask51.64 x 900
Day's Range50.13 - 51.04
52 Week Range44.30 - 68.88
Volume14,910,252
Avg. Volume14,873,327
Market Cap83.223B
Beta (3Y Monthly)0.84
PE Ratio (TTM)16.83
EPS (TTM)3.03
Earnings DateApr 24, 2019 - Apr 29, 2019
Forward Dividend & Yield1.64 (3.19%)
Ex-Dividend Date2019-01-03
1y Target Est56.64
Trade prices are not sourced from all markets
  • Why Is Bristol-Myers (BMY) Up 4% Since Last Earnings Report?
    Zacks12 hours ago

    Why Is Bristol-Myers (BMY) Up 4% Since Last Earnings Report?

    Bristol-Myers (BMY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Merck to Buy Immunotherapy Developer Immune Design for $300M
    Zacksyesterday

    Merck to Buy Immunotherapy Developer Immune Design for $300M

    Merck (MRK) plans to acquire Immune Design for $300 million in cash. Merck will pay $5.85 in cash for each share of Immune Design.

  • Business Wireyesterday

    Bristol-Myers Squibb Announces Filing of Definitive Proxy Statement in Connection with Proposed Merger with Celgene

    Bristol-Myers Squibb Company (BMY) today announced that it has filed definitive proxy materials with the U.S. Securities and Exchange Commission in connection with the Company’s pending merger with Celgene Corporation (CELG). Bristol-Myers Squibb will commence mailing the joint proxy statement / prospectus to its stockholders on or about February 22. The Bristol-Myers Squibb Special Meeting of Stockholders is scheduled to take place on April 12, 2019 at 10:00 a.m. Eastern Time.

  • Reuters2 days ago

    US corporates tap term loans as they look to avert downgrades

    US high-grade companies including Fiserv and Keurig Dr Pepper have increasingly turned to term loans, which are cheaper to issue and easier to prepay than longer-term bonds, as they prioritize debt reduction to avert credit rating downgrades. Heavy long-term debt loads incurred in large mergers and acquisitions (M&A), and in some cases slower than expected repayment of that acquisition debt, has spurred a wave of downgrades to the lowest investment grade rungs or even to junk status. Looking to prevent that, new borrowers are refinancing existing term loans with smaller new loans, while others are quickly applying excess cash flow to deleveraging, looking to show they can cut back on the debt loads incurred in costly M&A.

  • Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y
    Zacks2 days ago

    Bausch (BHC) Q4 Earnings Beat Estimates, Revenues Down Y/Y

    Bausch (BHC) Q4 earnings and revenues surpass estimates. However, guidance for 2019 is not impressive.

  • Benzinga2 days ago

    Merck To Buy Immune Design For $300M

    Biotech M&A is on a roll in 2019, with a couple of multi-billion dollar deals announced already, including Bristol-Myers Squibb Co (NYSE: BMY )'s proposed buy of Celgene Corporation (NASDAQ: CELG ) and ...

  • Reuters3 days ago

    PRESS DIGEST -Wall Street Journal - Feb 21

    The following are the top stories in the Wall Street Journal. - Johnson & Johnson said on Wednesday it received subpoenas from the U.S. Justice Department and the Securities and Exchange Commission seeking documents related to the safety of its signature baby powder and other talc-containing products.

  • The Wall Street Journal3 days ago

    Activist Investor Starboard Unhappy With Bristol-Myers’ Deal to Buy Celgene

    Activist investor Starboard Value LP is unhappy with Bristol-Myers Squibb Co.’s deal to buy rival Celgene Corp., and it has moved to install its own set of directors at Bristol-Myers. The hedge fund has nominated five potential directors, including its chief executive, Jeffrey Smith, and has been meeting with the drugmaker’s executives, Bristol-Myers said in a filing Wednesday. The activist proposal comes as Bristol-Myers has a deal in place to buy Celgene that was valued at $74 billion when it was announced earlier this year.

  • Reuters3 days ago

    Bristol-Myers says Starboard nominated five directors, bought shares

    Reuters reported last week that Starboard was working with a proxy solicitor to gauge the level of support among Bristol-Myers shareholders for the Celgene deal. If it finds enough discontent, Starboard could agitate against it. Bristol-Myers said Starboard informed the company it had bought roughly one million of its common shares.

  • CNBC3 days ago

    Starboard Value has 1 million-share stake in Bristol-Myers Squibb, has met with management

    Bristol-Myers Squibb confirms Starboard's stake in the company and says the $74 billion deal to acquire cancer drugmaker Celgene is "on track" to close during the third quarter.

  • Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct
    Zacks3 days ago

    Novo Nordisk Gets FDA Nod for Haemophilia Drug Esperoct

    Novo Nordisk (NVO) clinches the FDA approval for its biologics license application in favor of Esperoct to treat adults and children suffering haemophilia A.

  • Business Wire4 days ago

    Bristol-Myers Squibb Provides Update on Pending Transaction with Celgene

    Bristol-Myers Squibb Company (BMY) today provided an update on its proposed acquisition of Celgene Corporation (CELG). Bristol-Myers Squibb announced that it has filed an amended registration statement on Form S-4 with the Securities and Exchange Commission (“SEC”) in connection with Bristol-Myers Squibb’s proposed acquisition of Celgene.

  • TheStreet.com4 days ago

    Merck Shares Drop After Keytruda Treatment Fails Late-Stage Liver Cancer Trial

    shares slipped lower in pre-market trading Wednesday after the drugmaker said one of its key liver cancer treatments failed a late-stage trial only months after getting accelerated approval from the U.S. Food & Drug Administration. Merck said late Tuesday that its Keytruda treatment for patients with advanced liver cancer who were previously treated with systemic therapy did not meet the endpoints for overall survival when compared with placebo plus best supportive care. "While we are disappointed KEYNOTE-240 did not meet its co-primary endpoints, the results for overall survival, progression-free survival and objective response rate are generally consistent with findings from the Phase 2 study, which led to the accelerated approval of KEYTRUDA for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib," said chief medical officer Dr. Roy Baynes.

  • How to Replicate Hedge Fund Strategies with ETFs
    Zacks4 days ago

    How to Replicate Hedge Fund Strategies with ETFs

    Liquid alternative ETFs provide access to hedge fund strategies that are not correlated with major asset classes.

  • Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo
    Zacks5 days ago

    Bayer Obtains Full Rights to Vitrakvi From Lilly's Loxo

    Bayer (BAYRY) obtains full exclusive licensing rights for the global development and commercialization of Vitrakvi (larotrectinib) and BAY 2731954 (LOXO-195) from Loxo.

  • Starboard gauges Bristol-Myers shareholder support for Celgene deal
    Reuters8 days ago

    Starboard gauges Bristol-Myers shareholder support for Celgene deal

    The fund, run by Jeff Smith, may take no action, the sources added. Bristol-Myers shareholders will vote on the Celgene deal in April. While Celgene shares are pricing in some uncertainty over whether it will be completed, no major Bristol-Myers shareholder has voiced opposition publicly to the deal so far.

  • Moody's8 days ago

    Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Bristol-Myers Squibb Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • Reuters8 days ago

    Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients

    Nektar Therapeutics said on Friday some patients with advanced bladder cancer treated with a combination of its experimental treatment and Bristol-Myers Squibb Co's immunotherapy, Opdivo, showed signs of tumor reduction in an early-stage study. Of the 27 patients with urothelial cancer, 19 percent showed complete response after being treated with the combo therapy using Nektar's NKTR-214, according to data, which was presented at the Genitourinary Cancers Symposium in San Francisco. The disease, which can infect any part of the urinary tract including the renal pelvis and the bladder, is the sixth most common type of cancer in the United States, the company said.

  • Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates
    Zacks8 days ago

    Prothena's (PRTA) Q4 Earnings Beat, Revenues Miss Estimates

    Prothena's (PRTA) Q4 loss was narrower than expected, while revenues missed expectations.

  • InvestorPlace9 days ago

    Friday’s Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard

    U.S. stock futures are flat this morning but well off the overnight dips. In early morning trading, the futures on the Dow Jones Industrial Average are up 0.38% and S&P 500 futures are higher by 0.41%. Nasdaq-100 futures have added 0.49%.In the options pits, call buyers were still the busier bunch on Thursday, but the markets had a tizzy brought by the weakest retail sales report since 2009. We also had news that things are not going well with the China tariff deal. Now we are in a stalemate while we await the next meeting or headline. Wall Street is waiting for confirmation before they eliminate the risks from those fronts. The action was more cautious than Wednesday. We saw the options balance shift slightly more bearish, with only 18.1 million calls and 16.3 million puts during the session.However, there is still overall caution among many skeptics of this rally. The CBOE single-session equity put/call volume ratio inched up to 0.6. This is now almost at the 10-day moving average of 0.61.InvestorPlace - Stock Market News, Stock Advice & Trading TipsAlthough options activity was cautious on Thursday, there were a few standouts in options trading. Bristol-Myers Squibb (NYSE:BMY), Activision Blizzard (NASDAQ:ATVI) and Intel (NASDAQ:INTC) had unusual levels of options activity or an unusual mix. This typical is a precursor to sizable stock moves.Let's take a closer look: Bristol-Myers (BMY)BMY stock has seen better days. Last year started well for it, but after topping out in the middle of February, it went into a 35% correction from top to bottom. 2019 started even worse when the stock fell to a new low of $44.30 on Jan. 3 when they announced the Celgene (NASDAQ:CELG) buyout. * 10 Hot Stocks Leading the Market's Blitz Higher Since then, Bristol Meyers stock has rallied and now showing some appetite to continue even further. Options traders on Thursday traded 214% of its daily average. They were still split almost evenly between calls and puts but it does show their interest in it.This is an indication that there should be a move -- most likely the continuation of the current trend. Buying calls is a cheap way to bet on the upside. Conversely, buying puts is a cheap way to buy temporary protection while remaining long the stock. Here they are both active, so investors are still engaged.If the bulls can breakout through $51.50 area then they would have the opportunity to retest $52.90. If that happens, it would offer yet another upside breakout line. So what is happening here is that investors are using options to ride out this mini rally so they can get to bigger rewards above.This is a quality, healthy company whose stock is temporarily broken … but the company is not. The market eventually will fix this so that the trend reflects the actual company prospects. Activision Blizzard (ATVI)The worst may be over for Activision stock, at least for now. This stock, along with many in the sector, have been under severe pressure from major shifts in their customer trends. But it seems like ATVI is adjusting and managing their businesses to right the ship.I recently wrote an article on how to trade the short-term ATVI. In it I noted the breakout potential from $44.30 to $45.60. This upside potential has almost filled as of yesterday but there still is potential upside even above it.The ATVI zone around the recent high of $46.58 per share will now serve as the next breakout potential to target $48 per share and fill the entire Feb. 5 gap. It will need the general market's help and it may take a few days to do it. Eventually, this creep higher will break the long-term descending trend line of lower highs and a much bigger breakout will ensue.This is a long way of saying that the Activision stock has probably bottomed and that it will have a chance at recovering all the way back to $56 per share. There are areas of resistance at several spots along the way, the most major of which are at $49.50, $51.6o and $$53 per share. Intel (INTC)Intel stock mounted a respectable 14% rally off the December lows. The day it went into the earnings event, INTC stock was on the verge of a secondary breakout line. Unfortunately, Wall Street did not like the earnings report headline and the stock sold off as much as 8% when it opened.But this was a fake-out bear trap because since then, the stock has risen 10%. Now it is once more at the verge of another chance at that breakout. The measured move from that would target $56 per share. There will be resistance at $53.20 and $54.70.Now that the gap is almost closed, I weigh the odds of it being the target of this ongoing rally against the idea that this is a mega breakout with $56 per share as the eventual target.I was a bit disappointed that they gave the interim CEO the job for good, especially after such a long search period. But since then, investors have accepted the decision so it's no longer an overhanging issue and my feeling don't matter to how I trade it.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 10 Best ETFs You Can Buy * 7 Reasons Stock Buybacks Should Be Illegal * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? Compare Brokers The post Fridaya€™s Vital Data: Bristol-Myers Squibb, Intel and Activision Blizzard appeared first on InvestorPlace.

  • Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%
    Zacks9 days ago

    Strength Seen in AstraZeneca (AZN): Stock Soars 9.3%

    AstraZeneca (AZN) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

  • Business Wire9 days ago

    Opdivo (nivolumab) Plus Yervoy (ipilimumab) Shows Response in Pre-Treated Patients with Metastatic Castration-Resistant Prostate Cancer

    First I-O/I-O combination regimen to demonstrate response rates in this hard-to-treat patient population

  • Activist hedge fund Starboard nominates five directors to Bristol-Myers board
    CNBC Videos3 days ago

    Activist hedge fund Starboard nominates five directors to Bristol-Myers board

    CNBC's David Faber reports on the latest news regarding the Bristol-Myers acquisition of Celgene. The company announced in a press release that it will have a special shareholders meeting in April to vote on the Celgene deal. Activist hedge fund Starboard Value, which owns roughly $50 million of stock, has sent notice that it has nominated five directors to the company's board for its annual meeting.